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Abstract 
The concept of “fairness” is introduced and its position in the ethical systems of rights and virtues outlined. The 
application of such thinkings to the worlds of vaccines and vaccination is then examined in some detail. This 
domain stretches from the inception of the idea of a need for a prophylactic measure to counter a historic or modern 
disease, beit caused by an infectious or a non-infectious agent. At each stage of this process a view is taken as to the 
issues that arise from fair or unfair behaviours. This leads to conclusions that focus on the way we regulate the 
issuance of a licence to manufacture and sell a vaccine in addition to the emphasising the need to focus on 
immunogens that are both universal and cross-protective with regard to their being able to counter the disease 
causing properties of pathogens that can “change their outer surfaces”. A concluding look at the ethical principles 
that are engendered in this paper highlights the need to accept responsibilities to seek to improve the well-being of 
our societies both in kind and by adopting attitudes and behaviours that give a reality to the notions of the virtues of 
fairness and justice that is the theme of this work. 
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1. Introduction 
 
The world of vaccines and vaccination is presently driven by such terms as: efficacy, safety, consistency, 
cost/benefit, disease prevention and saving the lives of infants, pandemics, biodefense, the epitopes expressed by 
pathogens and the immune system, Good Laboratory/Manufacturing Practice and others. But at this time the word 
“fairness” is missing from this inventory. While the societies of our present world are clearly developing in ways 
that expands the gap between the rich and the poor, it is now necessary to revisit this situation with a view to 
rebalancing the distribution of benefits. By the appropriate development, production and distribution of vaccines we 
have a clear opportunity to contribute to this rebalancing operation.  
 
2. Being Fair; Acting Fairly; Seeking Fairness 
 
But before we apply the terms “fair”, “fairly” and “fairness” we have to examine their meaning. The Oxford English 
Dictionary has several full pages dealing with the word “fair” and its combination with other words. Perhaps it is 
possible to find a way into the meaning of this word if we start with the Latin word “fiera” which at first reading can 
be taken as “holiday”. On closer examination we arrive at meanings that take us to “periodical gatherings of buyers 
and sellers”. Yet, there are Nordic and Teutonic versions of this word that lead us to notions of “beauty, pleasing to 
the eye, lightness of colour, free from blemish and clear”. In addition to these connotations there is also a class of 
meanings which devolve about issues of “equity, legitimacy, free from bias, not taking undue advantage and 
disposed to concede every reasonable claim”. This leads us to John Rawls’ association of the words “fairness and 
justice” being two sides of the same coin. In his book “A Theory of Justice” (Harvard University Press, 1971) we 
have, “… one may think of justice as fairness and rightness as fairness as providing a definition or explication of 
the concepts of justice and right”(p111). It is noteworthy that the Hebrew word for justice tzedec ( צדק) is also used 
to denote fairness. So this thrust to achieve just outcomes in which the participants so appreciate the nature of the 
system such that they find a just and acceptable distribution of the goods of that system in association with the 
magnitude of their required contributions to that system.  
 
Should fairness be regarded as a right that is to be accorded to those who engage in the production and receipt of 
vaccines then the corresponding obligations and/or responsibilities have to be enunciated. An alternative (but not 
exclusive) view is that to be fair is a way of expressing a virtue; as in the Aristotelian virtue of justice that is also 
highlighted in a modern syntheses called “Principalism”  as exposited in the Belmont Report of 1979 (1). So, being 
fair is the expression of a personal character that is honed to be virtuous. But can this be left to be as it is? Training 
in being virtuous and expressing virtues was once part of a person’s education. Today schools, religious bodies and 
educational institutions hint at what might be required in this regard but do not in general put the expression of 
virtues as a focal aspect of the training of a citizen to be a member of society. Maybe it is time to put such thinkings 
back on the educational agenda. 
 
Having examined some of the implications of the use of the term “fairness” how may these concepts apply to the 
world of vaccines and vaccination?    
 
3. The world of vaccines and vaccination 
 
Vaccines are materials that are applied to a human or an animal with the intent of preventing the manifestation of a 
specific or general state of disease in that human or animal. The process of the application of the vaccine material is 
known as vaccination. 
 
To achieve the intention of disease prevention it is first necessary to define the disease. Today we recognise that 
there are broadly two classes of disease; those caused by infectious micro and macro organisms and diseases that do 
not require an infectious agent. In the former case we are familiar with diseases caused by viruses, bacteria, fungi 
and protozoans while macro-organisms such as tapeworms (Cestoda) and Schistosomes (Trematodes) are also 
troublesome. While latterly we have started to search for vaccines that can prevent or even cure human diseases 
such as cancer, atherosclerosis, Alzheimer’s disease, addiction, diabetes and cardiovascular afflictions. 
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4. From a recognisable disease to an effective vaccine used in the field 
 
4.1. The disease causing agent 
 
The first stage in the development of a vaccine is to acquire notions of the possible cause of the targeted disease. In 
this, where an infectious microorganism is suspected it is necessary to apply “Koch’s Postulates” which involve the 
demonstration that an entity removed from a diseased individual can, after growth and characterisation in pure 
culture, cause a similar disease in an uninfected individual. The infectious agent should then be isolated from the 
newly infected individual and shown to be indistinguishable from the originally isolated organism. This latter step 
can only be effected when the disease is not lethal and there are cures or treatments that render a diseased person 
well. Animal models may be used in this discovery process when the disease is lethal and/or incurable. 
 
The process of the discovery of the disease causing agent can raise issues of fairness. For example, the choice of 
individuals for the validation of  the nature of the infectious agent may involve, on the one hand volunteers 
(compensated by payments and after providing informed consent) or people who owe a debt to society (criminals) 
and wish for favourable treatment as a result of agreeing to being exposed to a risk of debilitation. A third option is 
to effect such studies in parts of the world where people are more inclined to come forward for little or no reward. 
Here there are serious issues of fairness which means that appropriate and additional compensations have to be 
delivered by, perhaps, commitments to the improvements of the healthcare facilities of those societies as and when a 
vaccine is developed.  
 
We assume that we can effect these experiments in animals without further considerations. Yet the guidelines for 
such work involves the evocation of the 3 R’s (Reduce, Refine, Replace) so that appropriate animals are chosen as 
far removed from sentient primates as possible, in as few in number as possible and when other, cell culture models, 
cannot be deployed. While it is clear that animals cannot enter into the same kind of relationship with humans as do 
humans, the way in which we treat animals gives messages to the rest of the community of humans of our intentions 
insofar as we respect and value life in all its forms (we may make exceptions for animals that threaten human life – 
some snakes, spiders, crocodiles, white sharks and pathogenic microorganisms). By creating this aura of caring for 
our fellow creatures we hope to make the depredations associated with the wars of the last century a thing of the 
past. 
 
 4.2.    From organism to immunogen 
 
An antigen is a material that evokes a response of the human or animal immune system; an immunogen generates a 
response of an immune system that may protect against the emergence of disease. In general it is not expected that 
such a response prevents the process of infection by a potentially pathogenic organism (sterile infection) but that 
once an infection has occurred its development to cause disease is curtailed. While the first epoch of vaccine 
development relied on the use of infectious materials derived from diseased individuals (smallpox) later 
developments beginning in the mid-19th century creatively and in a controlled way attenuated the pathogenicity of 
disease causing organisms and led to vaccines based on viable bacteria (Fowl Cholera, Anthrax, Tuberculosis) or 
viruses (Rabies, Yellow Fever, Influenza). An alternative approach used during this period was the use of the 
products of bacteria (inactivated toxoids – Tetanus and Diphtheria) killed bacteria (Pertussis) and killed viruses 
(Foot-and-Mouth, Newcastle Disease) (2). This latter epoch continues in various forms to the present day, 
notwithstanding the emergence in the last couple of decades of many new techniques that can be used to generate 
immunogenic materials from pathogens. The new and as yet unlicensed immunogens may be based on a knowledge 
of the genome of the pathogen, its proteome – from which epitopes that stimulate T-Cell responses may be 
identified - and a wide variety of ancillary materials that potentiate the immune response – ligands, adjuvants and 
stabilisers. It is the combination of an immunogenically active material with a potentiating agent which may be 
tailored to induce a particular type of immune response (either humoral – dependent on antibody molecules, or 
cellular – based on particular types of T-Cells, or both). 
 
It has recently become clear that it is possible to design “universal – cross protective” immunogens that protect 
vaccinees against a wide variety of subtypes and variants of the target pathogen (3). This renders the development of 
8   Raymond E. Spier /  Procedia in Vaccinology  8 ( 2014 )  5 – 11 
vaccines that are specific to a single subtype of the pathogen less than fair. Classically, this is the case for the 
Influenza vaccine. Here a new type of vaccine is made each year or season. Recent research has shown the 
practicability of making cross-protective vaccines which means that work on type-specific vaccines can be 
considered an act that is unfair to society. 
 
Where does the notion of fairness enter into the ways by which we arrive at an immunogen in consort with its 
potentiator? Firstly, decisions are made as to the worthiness of a disease for attention. It seems that there is a strong 
interest in the disease, influenza (possibly because it has been shown to have killed 40-100 million people in the 
years following World War I) rather than the common cold caused by the Rhinovirus which infects a significant 
portion of the population yearly and results in rendering the infectee susceptible to bacterial infections or a 
debilitating change in the bacteria that naturally are present on our outer surfaces.  We have paid much more 
attention to the diseases of childhood of the Developed World (Mumps, Measles, Rubella, Haemophilus influenza, 
Meningitis) and relatively little effort has gone into preventing Malaria, Tuberculosis and Schistsomiasis which are 
typically diseases prevalent in the Developing World. Is this fair? Those societies that can afford the research that 
may lead to a vaccine choose to work on the diseases that affect them the most. Other diseases take a secondary 
position. A second reason for seeking to develop a vaccine is the commercial motive. Vaccines protective against 
HepatitisB, Papilloma Virus and Rotavirus are examples of viruses for which vaccines have been developed and 
have resulted in commercial successes. A vaccine that would be protective against the Human Immunodeficiency 
Virus (HIV) is likely to be commercially successful were it to be developed and this explains the extensive 
investigations that have been and are yet on-going to achieve and effective vaccine protective against this virus. 
Whereas, there are diseases of the Developing World such as Dengue, Ebola, Japanese Encephalitis and 
Streptococcal diseases that are not receiving the attention that may be due to them. This leads us to the question: is it 
appropriate that the mechanisms that determine the selection of the diseases for which we seek vaccines are 
dependent on commercial motives, or the priorities of the Health Care facilities of developed countries or the 
willingness of Charitable Agencies to provide the necessary directions and funds?  Should these mechanisms be 
inadequate or indeed, unfair, how then may we go about selecting diseases for further attention? This latter question 
raises issues about how we see the development of the populations of the world in relation to the resources available 
for their sustenance. And this leads us to concepts of justice which seek to enhance the well-being and prosperity of 
all our societies. 
 
4.3. From immunogen to vaccine candidate 
 
To arrive at a situation where there is a vaccine candidate a vaccine developer has to achieve a number of goals. The 
first is to discover a reliable process that enables the large-scale manufacture of the immunogen. This has to be done 
in a reproducible manner with characterisable materials, process equipment and procedures in an environment that 
complies with “Good Manufacturing Practice”. While this work proceeds additional tests are effected to evaluate the 
safety of the putative vaccine. Such tests are done in cell cultures, laboratory animals and analytical devices.  
 
There are many choices to be made. The immunogen may be an organism that is inactivated or killed or alive and 
attenuated or one that is derived from a related disease of an animal. Parts of organisms (sometimes with attached 
conjugates) or the toxins they excrete are often used. When manufacturing a virus, the cell culture used may be one 
that uses cells that are in suspension or cells that are grown on solid surfaces as monolayers. Vaccines based on parts 
of organisms may be incorporated in to artificial viruses (virosomes or liposomes). Each of these process has 
advantages and disadvantages and there are always cost-of-production implications – although these tend to pale 
into insignificance when compared to the testing that has to be effected to ascertain a targeted and accepted level of 
safety. 
 
The basis for making the choices delineated above spin about issues of cost, reliability of consistent production, 
immunogenicity of the final product, method of delivery and the safety and/or reactogenicity of the final vaccine. 
Can any choice made in these areas be considered unfair? There is little doubt that the least expensive method of 
vaccine production is to be preferred – but often this choice is conditioned by the methods of vaccine production 
with which the manufacturer is familiar, is set up for and is comfortable. Elements of unfairness may also be found 
in the way a putative manufacturer responds to data for vaccine potency and safety. Animal systems are notorious 
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for providing data that does not relate to what happens in the target human or animal. When testing a vaccine 
candidate designated for use in humans, the use of non-human primates is called for. How many such animals 
should be exposed to the vaccine, the placebo and an agent that can cause a similar infection in the test animal? As a 
general rule, the more striking the effects, the fewer the animals needed. To be first in the market place with an 
authorised product is a goal that drives many manufacturers. On the other hand the reputation of the manufacturer is 
wholly dependent on marketing products whose benefit to cost or harm ratio is consistently high. So risk aversion is 
the approach that is adopted. That is up until the time the Regulatory Agency which issues the licence to 
manufacture and sell the vaccine has made its final decision. 
 
4.4. From candidate to product in the market –via the gateway of the Regulatory Agency 
 
Vaccines occupy a unique niche in the social scheme of things. This stems from the penetrational delivery of the 
vaccine – a material related to a disease-causing organism - into a person who is in good health. There is and must 
always be an element of a risk of a vaccine caused adverse event. On the other hand, the prevention of disease for 
millions of vaccine recipients has to be a counterbalancing benefit. 
 
Vaccines cannot be marketed for human use in the developed world without a licence to manufacture and sell issued 
by a Regulatory Authority. To acquire such a licence the vaccine is subjected to testing in three phases; Phase I – a 
test in several 10s of people for safety; Phase II – a test in several hundreds/thousands of people for safety, efficacy 
(superior potency to anything that exists at that time) and the demonstration of the ability to prepare the vaccine 
consistently by providing production and analytical data on three consecutively produced vaccine lots; Phase III – 
the demonstration of the efficacy and safety of the vaccine and its ability to decrease disease in a target population 
involving several to hundreds of thousands of subjects; taking several (2-10 years) and costing $0.5-1 billion or 
more. A Phase IV is also recognised as a post-licensure reportage of adverse events or abreactions to the vaccine. 
 
It is clear from the brief description of the process whereby a licence is obtained that most of the cost incurred 
before a vaccine may be sold on the market is attributable to the testing that is effected in Phase III. The 
consequence of this is that: 
x The vaccine when available on the market is expensive (the manufacturer has to recoup the costs 
incurred in Phase III during the remaining time available on whatever patent protections have been 
obtained). This puts the vaccine out of the reach of the people and societies that need the vaccine 
the most. 
x There is a further cost in that while the vaccine is being tested people whose health would be 
protected are denied that protection so there are diseased individuals who would have been 
protected were the vaccine available. 
x The benefits that accrue from Phase III testing are minimal; the safety and efficacy of the putative 
vaccine have already been established by the end of Phase II (or else the manufacturer would not 
have been so bold as to venture into the major spending commitment necessitated for Phase III 
trials). What is derived from the Phase III exercise is an increase in the reliability of the protective 
efficacy/adverse side reactions ratio. (See reference (4) for a further and more extensive discussion 
of this situation) 
x It is possible to use Phase IV to continue to monitor the progress of the vaccine in the society at 
large – and this monitoring and reporting system should be enhanced, extended and promoted with 
vigour. It should be noted that there have been vaccines that have passed all three phases of testing 
and then have had to be withdrawn from circulation as a result of unacceptable adverse events 
(rotavirus, Lyme Disease and Swine Influenza vaccines have been so treated). 
 
If the contentions listed above are valid then it has to be unfair to our societies to be denied the benefit of the use of 
vaccines until Phase III has been satisfactorily passed. While it is argued that confidence in the Vaccine Industry is 
contingent upon vaccines being free from causing harm the message that each and every intervention that humans 
apply to themselves (drugs, alcohol, food, transportation systems, weapons etc.) incurs a real and defined risk of 
realising a harm should be widely canvassed. 
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The other issue that may be laid at the feet of the Regulatory Authority is that the cost/benefit ratio of the use of a 
vaccine in different societies is not identical. Where the disease is more prevalent and the people are less robust as a 
result of malnutrition a vaccine would have more beneficial effects than in a society where the disease is rare and 
where people can fend off the effect of having been infected. This means that greater benefits may be realised and 
therefore greater costs may be sustained. Such costs may result from accepting the raising of the probability of an 
adverse event.  
 
A corollary to this is that the standards required by different countries should be appropriate for the country 
where the vaccine will be deployed. The harmonization of standards over all countries is not in the interests of those 
peoples who would be denied vaccines because the cost of producing and testing a vaccine to a higher – and 
universally acceptable - level reduces the ability to run a vaccination campaign. This would be compatible with a 
policy of introducing fairness in considerations of the production and use of vaccines. 
 
 4.5 Vaccines in the field 
 
There are many fields. Some are run by State Controlled Health Systems while others rely wholly on Free 
Enterprise. Some are in wealthy countries and others in countries where the people experience hunger and danger on 
a daily basis. A vaccine can be an effective preventer of disease in most social situations. Most vaccines are 
developed in wealthy countries. In such countries it is not uncommon for the price paid for a vaccine to reach $100 -
1000 for one or each of three doses. Vaccines that have had a long run in the market and have more than paid back 
the investors or companies that have financed their development can be manufactured for much less that $1 per dose 
(not including testing, quality control and the costs of packaging, labelling, storage, transportation, distribution and 
application). In making a judgement as to the fairness of this situation, it is meet to balance the commercial 
investment and the risks associated with that investment (the magnitude of which will depend on the other vaccine 
candidates that did not achieve licensure and had to be dropped) with the social need and the ability to pay for the 
vaccine. 
 
There is a case to be made for the production of vaccines to be made the responsibility of the State. This enables the 
“free” provision of vaccines to all members of the population (as appropriate) and promotes the development of 
Herd Immunity. Countries such as Australia, Holland and many others work in this way. In the United Kingdom a 
decision made in March, 2014 to provide to children a newly licensed vaccine protective against the Neisseria 
Meningitidis type B bacterium freely has stepped around the situation where this vaccine was previously purchased 
at up to £600/dose in the marketplace. Other countries benefit from the vaccination campaigns that are run by 
UNICEF (5) that are financed by the GAVI alliance (The GAVI Alliance (formerly the “Global Alliance for 
Vaccines and Immunisation”) which is a public-private global health partnership committed to increasing access to 
immunisation in poor countries (6). This alliance calls on the financial and sustaining commitment of Foundations 
(Bill and Melinda Gates Foundation), National Governments, The World Bank and individual philanthropists (7). 
Money (billions of dollars) channelled through this alliance has financed the vaccination of billions of children in 
developing countries over the last several years since its inception in 1999. 
 
Notably, efforts to eradicate Polio have depended on the support of GAVI and have distributed vaccine at zero cost 
to the recipients to the extent where the 300,000 annual cases of Polio in the latter years of the previous century have 
declined to 200-500 cases in 2013. Efforts to vaccinate susceptible populations have recently redoubled 
notwithstanding the murders of 12 dedicated and committed vaccinators in Nigeria and Pakistan. 
 
There is little doubt that current efforts applied to delivering childhood vaccines to the children in the developing 
world has redressed a grievous unfairness in the application of vaccines world-wide. But this has to be seen as the 
beginning of the story. New vaccines (Papilloma virus, Pneumococcal conjugates, Varicella, Cholera, Rotavirus, 
Japanese Encephalitis and diseases caused by Meningococci) that protect juveniles, adults and older people are 
becoming available. At present these are both expensive and are used almost exclusively in the developed world. 
And with new techniques for immunogen discovery and production we may expect many more potentially valuable 
prophylactic agents to emerge from manufacturers in the near future – protective against the non-infectious diseases 
as well as the infectious diseases. How we handle the pricing and distribution of these novel vaccines will challenge 
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authorities, alliances and agencies world-wide; and not the least from the point of view of the delivery of “fairness”.    
 
5. Conclusions 
 
It is time the word “fairness” entered into the mainstream vocabulary of those engaged in the production, application 
and receipt of vaccines. In so doing it would seem that this notion of fairness is presented as a “right” that the 
members of all societies possess. This requires that there should be some commitment from those benefiting from 
the use of vaccines to the improvement of the well-being of the societies they populate. Clearly, when the vaccine 
recipient is a baby, infant or young child, such a commitment is out of the question. However, it could be made 
incumbent on the parent or guardian of the child to recognise a benefit freely given as a right has to be compensated 
by a commitment that is commensurate with the benefit received by such individuals.  
 
It is also important to engage with the Regulatory Agencies to require them to discharge their duties with a greater 
regard to the fairness of their dealing with the vaccine manufacturers and the society at large. It is not fair to require 
such extensive testing that vaccines do not emerge from the maw of the agencies until there has been a great 
expenditure of wealth and passage of time. The disadvantages that result from such a process do not compensate for 
the increase in the confidence that the agency has in the potency and safety of the vaccine. It would be more fair 
were the agency to license the use of the vaccine at as early a time as is feasible and then rely on an augmented 
surveillance apparatus to monitor the use of the licensed vaccine in the field.  
 
Finally, it is necessary to improve the immunogens that are sought to protect against diseases that are caused by 
pathogens that express subtype variations. It is a matter of fairness to our societies that those sponsoring the research 
into vaccine immunogen definition urge the vaccine developers to make the cross-protective, universal vaccines that 
release our societies from yearly vaccinations against Influenza and from having to make vaccines with many 
different immunogens to cover the varieties of the pathogen that are encountered in the field. In this way we may, 
with confidence, approach the problems which have bedevilled efforts to achieve prophylaxis due to the many 
variants of the pathogen (e.g. Rhinovirus, Gonorrhoea, Human Immunodeficiency Virus, Streptococci, Enteric 
bacteria, Salmonellae, Malaria).    
 
We are in a position today to radically review and overhaul the methods that have given us magnificent and 
successful vaccines. By introducing the concept of fairness into the world of vaccines and vaccination it may be that 
these changes and enhancements arrive sooner.   
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